OmniAb, Inc.
Dale Lee has extensive work experience in the accounting field. Dale is currently working as the Associate Director of Accounting at OmniAb, Inc. starting from October 2022. Prior to that, they held the position of Senior Manager of Accounting at Arena Pharmaceuticals, Inc. from October 2021 to October 2022. Before that, Dale worked at Cubic Corporation as the Corporate Accounting Sr. Manager from August 2019 to October 2021. Dale also worked at Cubic Global Defense, where they held several roles including Cost Accounting Sr. Manager, Cost Accounting Manager, and Cost Accounting Supervisor from 2017 to 2019. Dale's past experience includes working at Cubic Corporation as the Revenue Recognition Supervisor from December 2015 to February 2017, Revenue Recognition Sr. Analyst from April 2014 to December 2015, and General Accountant from August 2012 to April 2014. Prior to their career in accounting, Dale served in the US Navy as a Training Officer from November 2007 to August 2009 and as a Division Officer from June 2005 to October 2007.
Dale Lee completed their education with a Bachelor of Science (BS) in Business Administration from the University of Southern California in 2005. Dale further pursued a Master of Science in Accountancy from San Diego State University, graduating between 2009 and 2011. In 2013, Dale obtained the certification of Certified Public Accountant from the California Board of Accountancy. Later, in 2014 to 2015, they enrolled in San Diego State University to earn a Certificate in Contract Management.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.